Role of Autophagy in Progression of Liver Fibrosis in Chronic Hepatitis B Patients on Antiviral Treatment

Atefeh Sadidoost (✉ dr.at.sdt@gmail.com)

Shiraz Medical School: Shiraz University of Medical Sciences <https://orcid.org/0000-0002-2921-987X>

Kamran B. Lankarani

Shiraz Medical School: Shiraz University of Medical Sciences

Research Article

Keywords: autophagy, Hepatitis B virus, cirrhosis, Beclin-1, LC3, fibrosis, antiviral , HCC, ductular reaction, hepatic stellate cells

Posted Date: January 24th, 2022

DOI: <https://doi.org/10.21203/rs.3.rs-1258001/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License. [Read Full License](#)

Abstract

Introduction: Despite antiviral treatment, there are patients with chronic hepatitis B (CHB) who progress to cirrhosis. Enhancement of autophagy has been implicated in the proliferation of hepatitis B in hepatocytes. This study was designed to evaluate the role of autophagy in the progression of liver fibrosis in patients on antiviral therapies and negative viral load.

Methods: Patients on anti-hepatitis B nucleotide treatments for at least two years and had not been cirrhotic at baseline but who later developed cirrhosis were identified. For the control group, patients who were on the nucleotide regimens and did not have cirrhosis at baseline or follow-up were randomly selected from our registry. Serum Beclin-1 and LC3 measured by enzyme-linked immunosorbent tests were compared between two groups.

Results: Beclin-1 level was higher in those with cirrhosis, but no statistical difference was seen for the level of LC3.

Conclusion: Autophagy may have a role in progression to cirrhosis in patients with CHB. Future prospective studies are required to find the effect of blockage of autophagy on liver disease progression in this group.

Introduction

Hepatitis B virus (HBV) is a prevalent double-stranded DNA virus that is one of the significant risk factors for hepatocellular carcinoma (HCC) and liver cirrhosis worldwide (1–6). More than 255 million people are infected with chronic HBV (CHB) worldwide (7). In recent years, World Health Organization reported a silent HBV pandemic and estimated that only 1.7% of all eligible HBV cases receive treatment globally (8).

The risk of liver cirrhosis is higher in those with higher serum levels of the HBV DNA, and suppression of viral replication has been shown to reduce the risk of the development of cirrhosis and HCC in these patients (10).

Other factors, including coinfection with hepatitis D virus, hepatitis B e-antigen positivity, concomitant diabetes mellitus, and advanced age, increase the risk of progression to cirrhosis (10–13). Alternatively, there are patients with extremely high levels of HBV DNA who have no liver disease progression through the so-called immune tolerance state (14).

The ductular reaction (DR) is a typical response to injury observed in various liver diseases. Autophagy activation is required for the mesenchymal transition during the DR and plays an essential role in the pathogenesis process of cirrhosis (15). Several studies revealed that DR is positively associated with an elevated autophagic marker during cirrhosis development (16). Blockade of autophagy-mediated processes could provide novel opportunities to prevent or reverse cirrhosis.

Autophagy is the primary degradation system in somatic cells. Generally, eukaryotic autophagy includes different pathways to degenerate the short-lived protein (proteasome) and the plasma membrane and extracellular (lysosome) (17). Autophagy showed protective properties against infections, the physical stress of exercising, fasting, and cancers (18). Although autophagy demonstrated a valuable role in preventing the development of cancers at initial stages, this mechanism later provides the required energy for cancer cells and promotes tumor proliferation (19).

There are several reports of induction of autophagy by chronic HBV infection (20). This activation might be more prominent in HCC in the setting of chronic HBV infection (21). It is proposed that the X protein of HBV promotes viral proliferation and resistance through the regulation of phosphatidylinositol-3-kinase class III and c-myc, which is an essential step in autophagy (22–25). Therefore, developing therapies targeting autophagy may have a role in delaying or even regressing the liver injury induced by HBV. These autophagy-based treatments may also have a role in treating fatty liver disease and HCC (9, 18, 26).

Beclin-1 is an important autophagic agent and plays a crucial role in autophagosome formation (27–29). Moreover, the association of Beclin-1 with multiple disorders, such as fatal Sindbis Virus pathogenesis, has been proved many years ago (30). Both in vivo and in vitro models demonstrated that hepatic stellate cells (HSC) promotion have an association with activation of autophagy-mediated by several molecules, including LC3-II

(31, 32). It has been shown that both defective basal levels of autophagy and stress-induced increases in autophagy are equally important in promoting liver fibrosis (33).

This study was designed to investigate the possible role of autophagy in the progression of liver fibrosis in those who had adequate viral suppression.

Methods

Patients

Among the patients with chronic hepatitis B in Mottahhari hepatitis clinic affiliated to Shiraz University of medical science who received antivirals and had no cirrhosis in baseline,

we identified those who developed cirrhosis despite at least two years of oral nucleotide treatment and negative HBV DNA at the time of the study.

Exclusion and later diagnosis of cirrhosis at baseline and then in follow-up were with clinical evaluation, imaging including fibroscan and

biochemical markers of fibrosis. Excluded were patients with concomitant comorbid diseases including diabetes mellitus, those who used alcohol at any amount, patients with HDV or HCV infection, hemochromatosis, those who had BMI more than 30 at baseline or during follow up. Those who used any drug other than tenofovir in the past two months were also excluded.

All patients were on Tenofovir disoproxil fumarate for at least two years and had undetectable HBV DNA at the time of the study.

For the control group, we randomly selected from the digital files those who had the same characteristics but had not developed evidence of cirrhosis in their follow-up.

Ethics

This study is approved by the local ethics committee of Shiraz University of Medical Sciences. (Ethic code: IR.SUMS.MED.REC.1399.542) All patients signed a standard informed consent and were aware of the purposes of the study.

Study Design

The case group was selected among cirrhotic patients (ultimately 16 cases). Cirrhosis diagnosis was confirmed with transient elastography and clinical, laboratory, or endoscopic evidence, including thrombocytopenia, peripheral cirrhosis stigmata, and esophageal varices. These patients were not cirrhotic at baseline, and any other pathologic condition or disease could not explain the progression to cirrhosis. The control group (ultimately 14 cases) was selected from non-cirrhotic CHB followed up in Motahhari hepatitis clinic, Shiraz University of Medical Sciences, during the same period.

Serum Sampling and Measurement

Blood samples of studied patients (10cc) were taken by a venous puncture at the hepatitis clinic and prepared by centrifuge to separate serum and DNA components. Separated serum was stored in a -20°C freezer until the analysis procedure. Serum Beclin-1 and LC3 levels were evaluated by enzyme-linked immunosorbent assay (Sunlong Biotech Co. Ltd, China) in the research laboratory of Shiraz medical university, faculty of biochemistry. The process of serum assessment was carried out based on the intra-assay coefficient of variation (CV) less than 10%, inter-assay CV less than 12%, and lower detection limit of 1 pg/mL. Other Biochemical values were extracted from digital files in the hepatitis clinic. Serum transaminases levels such as aspartate aminotransferase (AST), alanine aminotransferase (ALT), and serum Alpha-fetoprotein levels were assessed by commercial Kits.

Statistical Analysis:

All variables were expressed as the mean $\pm$ SD. The statistical differences between case and control groups were tested with the paired sample T-test to pairwise comparisons. Besides, covariance analysis was done for age, gender, treatment duration, and transaminases levels. All data were analyzed using SPSS software (version 21.0; SPSS, Chicago, IL, USA).

Results

All Cases admitted in this study were chronic hepatitis B patients who had been treated for viral hepatitis B for at least four years.

In all cases, HBV DNA was negative.

Totally 30 patients were enrolled in this study. Diagnosis of cirrhosis was confirmed based on clinical and laboratory findings and transient elastography. Sixteen cases (53.3%) had developed cirrhosis despite treatment and proper virologic response. The other 14 cases (46.6%) were not cirrhotic. The characteristics of the two groups are shown in Table 1.

Table 1
Relationship of demographic and biochemical factors between cirrhotic and non-cirrhotic patients

		Age	Treatment duration	AST	ALT	PLT	Hemoglobin	AFP	BECLIN	LC3
Cirrhotic patients	Total number	16	16	16	16	16	16	16	16	16
	mean	60.9	11.3	41.2	39.4	149000	14.4	4.6	1283	168
	Std. Deviation	8.5	4.8	25.4	17.3	48000	1.4	1.8	244	31
Non cirrhotic patients	Total number	14	14	14	14	14	14	14	14	14
	Mean	49.1	10	26.6	31.4	215000	14.2	2.4	1063	150
	Std. Deviation	10	4.2	7.9	16.2	56000	1.7	1.9	257	16
Relationship between cirrhotic and non cirrhotics	P value†	0.002	0.446	0.049	0.205	0.002	0.679	0.005	0.024	0.065
	P value‡								0.008	0.290
† Based on independent t-test										
‡ Analysis of covariance adjusted by gender, age, treatment duration and transaminases										

The mean age of cirrhotic and non-cirrhotic patients was 60.9 ± 8.5 and 49.1 ± 10 respectively, according to independent sample t-tests mean age of the cirrhotic group was significantly higher than the non-cirrhotic group ($P=0.002$). The mean duration of treatment with antiviral was 11 years in the cirrhotic group which was not significantly different from 10 years in the non-cirrhotic group.

The platelet count was lower ($P:0.002$), AST and serum alpha-fetoprotein concentration both were higher in the cirrhotic patient's group ($P:0.005$). Hemoglobin concentration and alanine aminotransferase were lower in the cirrhotic group, but the difference was not statistically significant.

Beclin concentration was higher in the cirrhotic patient's group than the not cirrhotic patients' group, and the difference was statistically significant ($P:0.024$). Plasma concentration of LC3 was higher in the cirrhotic patient's group, but the difference

was not statistically significant (P:0.065)

After adjustment for gender, age, treatment duration, and level of serum transaminases based on covariance analysis, the mean plasma concentration of Beclin was still significantly higher in the cirrhotic patient group (0.008). Covariance analysis for adjustment for age, gender, treatment duration, and transaminases level revealed that mean LC3 concentration was not significantly different in both groups (P: 0.290) (Table 1).

Discussion

In this series of patients with CHB on long-term oral nucleotide, all with negative HBV DNA, those who progressed to cirrhosis had higher levels of Beclin-1.

Some patients progressed to cirrhosis in this series despite antiviral treatment, which may indicate that viral suppression by nucleotides through inhibition of HBV polymerase or incorporation into the nascent DNA strand causing chain termination is not sufficient stalling progression of liver disease. Autophagy may be one of the possible mechanisms driving this progression. Beclin-1, one of the early phases of autophagy markers, was higher in these patients, which may be a piece of evidence for this hypothesis.

It has been shown that HBV uses autophagy as a mechanism for its proliferation within cells. This mechanism may still be active despite viral suppression and lead to fibrosis and cirrhosis, at least in some patients.

Autophagy has been implicated in the development of cirrhosis due to other etiologies. This may act through activation of mesenchymal cells and enhancing collagen production and ultimately fibrosis.

Autophagy is a common mechanism in natural cells for providing required energy and materials, but in some cases, adverse effects of the autophagy system had been observed (34). It could be a double sword enhancing the proliferation of pathogens and abnormal cells, including malignancy. Autophagy has been implicated in the proliferation of HBV (40, 41) and hepatitis C virus infection (42, 43)

Several recent studies have shown enhanced autophagy as a mechanism for developing HCC (35, 36) and fatty liver disease (37–39). Autophagy is also implicated in innate and adaptive immune responses to viral hepatitis, including HBV (21). Studies on HCV pathogenesis showed that this hepatic virus uses cellular autophagy to favor viral replication and noticeably increases LC3 (44). This may further modulate the course of chronic liver disease.

Focusing on autophagy introduces a new opportunity to prevent and even reverse fibrosis in patients with chronic liver disease from any cause, especially CHB and CHC. Downregulation of autophagy in HSC has been linked to the attenuation of liver fibrosis (45, 46). We have previously shown that the use of chloroquine as a suppressor of autophagy suppresses HCV replication (47, 48).

Although this study has shown that serum Beclin-1 as a marker of autophagy was higher in patients who developed cirrhosis despite antiviral treatments, one can argue this is the result rather than the cause of fibrosis.

Cirrhosis is a complex and multifactorial state, and several mechanisms may act, which might be different in cirrhosis due to different etiologies. Therefore, further studies are required to investigate the exact relationship between autophagic markers and cirrhosis.

Although none of the patients had not cirrhosis based on clinical, endoscopic, and imaging and liver biopsy when available, some may have subclinical cirrhosis from the beginning. A prospective study is needed to see the progression. Tissue studies may further show the events at the molecular level. Our series was a small series from a single center which is another limitation of our study.

In conclusion, our study shows that at least in some patients with CHB, autophagy may have a role in the progression of cirrhosis despite adequate viral suppression. Targeting Beclin-1 and other autophagy mediators may lead to new promising therapies to prevent or even reverse HBV-related liver fibrosis.

Declarations

Data availability

The data that support the findings of this study are available from the corresponding author

Ethics approval

This study was approved by the local research ethics committee of Shiraz University of Medical Sciences. (Ethic code: IR.SUMS.MED.REC.1399.542), and all the patients signed a standard informed consent and were aware of the purposes of the study.

I, the corresponding author, give my Consent for the publication of manuscript in the journal of Hepatology International

Author's Contributions:

Kamran Bagheri Lankarani led all aspects of the study, including defining the research question, overseeing the recruitment effort, finalizing the methodology, interpretation of data and writing the manuscript. Atefeh Sadidoost led the administration of the survey, data management and contributed to writing up the manuscript. All authors provided final approval for publication.

Conflict of interest:

Authors have no conflicts of interest

References

1. Yan H, Zhong G, Xu G, et al. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. *elife*. 2012;1:e00049.
2. Glebe D, Bremer CM, editors. The molecular virology of hepatitis B virus. *Seminars in liver disease*. Thieme Medical Publishers; 2013.
3. Sarin S, Kumar M, Lau G, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. *Hepatology international*. 2016;10(1):1–98.
4. Fattovich G, editor Natural history and prognosis of hepatitis B. *Seminars in liver disease*; 2003: Copyright© 2002 by Thieme Medical Publishers, Inc., 333.
5. Poh Z, Goh B-BG, Chang P-EJ, Tan C-K. Rates of cirrhosis and hepatocellular carcinoma in chronic hepatitis B and the role of surveillance: a 10-year follow-up of 673 patients. *Eur J Gastroenterol Hepatol*. 2015;27(6):638.
6. Yang JD, Kim WR, Coelho R, et al. Cirrhosis is present in most patients with hepatitis B and hepatocellular carcinoma. *Clin Gastroenterol Hepatol*. 2011;9(1):64–70.
7. Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. *The Lancet*. 2015;386(10003):1546–55.
8. Organization WH. Hepatitis B. 2020 [Available from: [https://www.who.int/news-room/fact-sheets/detail/hepatitis-b#:~:text=WHO%20estimates%20that%20in%202015,\(i.e.%20primary%20liver%20cancer\)](https://www.who.int/news-room/fact-sheets/detail/hepatitis-b#:~:text=WHO%20estimates%20that%20in%202015,(i.e.%20primary%20liver%20cancer).)].

9. Saito T, Ichimura Y, Taguchi K, et al. p62/Sqstm1 promotes malignancy of HCV-positive hepatocellular carcinoma through Nrf2-dependent metabolic reprogramming. *Nature communications*. 2016;7(1):1–16.
10. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. *Jama*. 2006;295(1):65–73.
11. CHEN CJ, YU MW, LIAW YF. Epidemiological characteristics and risk factors of hepatocellular carcinoma. *Journal of gastroenterology hepatology*. 1997;12(9-10):294–308.
12. You SL, Yang HI, Chen CJ. Seropositivity of hepatitis B e antigen and hepatocellular carcinoma. *Annals of medicine*. 2004;36(3):215–24.
13. Yang H-I, Lu S-N, Liaw Y-F, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. *N Engl J Med*. 2002;347(3):168–74.
14. Brown A, Goodman Z. Hepatitis B-associated fibrosis and fibrosis/cirrhosis regression with nucleoside and nucleotide analogs. *Expert Rev Gastroenterol Hepatol*. 2012;6(2):187–98.
15. Hung T-M, Huang Y-J, Lin Y-C, Chen Y-H, Wu Y-M, Lee P-H. A critical role of autophagy in regulating the mesenchymal transition of ductular cells in liver cirrhosis. *Scientific reports*. 2019;9(1):1–12.
16. Sasaki M, Yoshimura-Miyakoshi M, Sato Y, Nakanuma Y. A possible involvement of endoplasmic reticulum stress in biliary epithelial autophagy and senescence in primary biliary cirrhosis. *Journal of gastroenterology*. 2015;50(9):984–95.
17. Mizushima N, Komatsu M. Autophagy: renovation of cells and tissues. *Cell*. 2011;147(4):728–41.
18. Levine B, Kroemer G. Autophagy in the pathogenesis of disease. *Cell*. 2008;132(1):27–42.
19. Vega-Rubín-de-Celis S. The role of Beclin 1-dependent autophagy in cancer. *Biology*. 2020;9(1):4.
20. Lin Y, Zhao Z, Huang A, Lu M. Interplay between Cellular Autophagy and Hepatitis B Virus Replication: A Systematic Review. *Cells*. 2020;9(9):2101.
21. Tian Z, Wang M, Yao N, et al. Expression of autophagy-modulating genes in peripheral blood mononuclear cells from familial clustering patients with chronic hepatitis B virus infection. *Archives of virology*. 2019;164(8):2005–13.
22. Sir D, Ann DK, Ou J-HJ. Autophagy by hepatitis B virus and for hepatitis B virus. *Autophagy*. 2010;6(4):548–9.
23. Yuen MF, Chen DS, Dusheiko GM, et al. Hepatitis B virus infection. *Nat Rev Dis Primers*. 2018;4:18035.
24. Wang J, Chen J, Liu Y, et al. Hepatitis B virus induces autophagy to promote its replication by the axis of miR-192-3p-XIAP through NF kappa B signaling. *Hepatology*. 2019;69(3):974–92.
25. Zhang L. Autophagy in hepatitis B or C virus infection: An incubator and a potential therapeutic target. *Life sciences*. 2020;242:117206.
26. Wei Y, Pattingre S, Sinha S, Bassik M, Levine B. JNK1-mediated phosphorylation of Bcl-2 regulates starvation-induced autophagy. *Molecular cell*. 2008;30(6):678–88.
27. Aita VM, Liang XH, Murty V, et al. Cloning and genomic organization of beclin 1, a candidate tumor suppressor gene on chromosome 17q21. *Genomics*. 1999;59(1):59–65.
28. Liang C, Lee J-s, Inn K-S, et al. Beclin1-binding UVRAG targets the class C Vps complex to coordinate autophagosome maturation and endocytic trafficking. *Nat Cell Biol*. 2008;10(7):776–87.
29. Zhong Y, Wang QJ, Li X, et al. Distinct regulation of autophagic activity by Atg14L and Rubicon associated with Beclin 1–phosphatidylinositol-3-kinase complex. *Nat Cell Biol*. 2009;11(4):468–76.
30. Liang XH, Kleeman LK, Jiang HH, et al. Protection against fatal Sindbis virus encephalitis by beclin, a novel Bcl-2-interacting protein. *Journal of virology*. 1998;72(11):8586–96.
31. Friedman SL. Mechanisms of hepatic fibrogenesis. *Gastroenterology*. 2008;134(6):1655–69.
32. Thoen LF, Guimarães EL, Dollé L, et al. A role for autophagy during hepatic stellate cell activation. *J Hepatol*. 2011;55(6):1353–60.
33. Principe DD, Lista P, Malorni W, Giammarioli AM. Fibroblast autophagy in fibrotic disorders. *J Pathol*. 2013;229(2):208–20.

34. White E. Deconvoluting the context-dependent role for autophagy in cancer. *Nature reviews cancer*. 2012;12(6):401–10.
35. Takamura A, Komatsu M, Hara T, et al. Autophagy-deficient mice develop multiple liver tumors. *Genes Dev*. 2011;25(8):795–800.
36. Wu D-H, Jia C-C, Chen J, et al. Autophagic LC3B overexpression correlates with malignant progression and predicts a poor prognosis in hepatocellular carcinoma. *Tumor Biology*. 2014;35(12):12225–33.
37. Ding WX, Li M, Chen X, et al. Autophagy reduces acute ethanol-induced hepatotoxicity and steatosis in mice. *Gastroenterology*. 2010;139(5):1740–52.
38. Lin C-W, Zhang H, Li M, et al. Pharmacological promotion of autophagy alleviates steatosis and injury in alcoholic and non-alcoholic fatty liver conditions in mice. *Journal of hepatology*. 2013;58(5):993–9.
39. Fukuo Y, Yamashina S, Sonoue H, et al. Abnormality of autophagic function and cathepsin expression in the liver from patients with non-alcoholic fatty liver disease. *Hepatology research*. 2014;44(9):1026–36.
40. Sir D, Tian Y, Chen W-I, Ann DK, Yen T-SB, Ou J-hJ. The early autophagic pathway is activated by hepatitis B virus and required for viral DNA replication. *Proceedings of the National Academy of Sciences*. 2010;107(9):4383-8.
41. Qu X, Yu J, Bhagat G, et al. Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene. *J Clin Investig*. 2003;112(12):1809–20.
42. Sir D, Chen WI, Choi J, Wakita T, Yen TB, Ou JhJ. Induction of incomplete autophagic response by hepatitis C virus via the unfolded protein response. *Hepatology*. 2008;48(4):1054–61.
43. Rautou P-E, Cazals-Hatem D, Feldmann G, et al. Changes in autophagic response in patients with chronic hepatitis C virus infection. *Am J Pathol*. 2011;178(6):2708–15.
44. Yeganeh B, Moghadam AR, Alizadeh J, et al. Hepatitis B and C virus-induced hepatitis: Apoptosis, autophagy, and unfolded protein response. *World journal of gastroenterology*. 2015;21(47):13225.
45. Hernández-Gea V, Ghiassi-Nejad Z, Rozenfeld R, et al. Autophagy releases lipid that promotes fibrogenesis by activated hepatic stellate cells in mice and in human tissues. *Gastroenterology*. 2012;142(4):938–46.
46. Thoen LF, Guimarães EL, Dollé L, et al. A role for autophagy during hepatic stellate cell activation. *Journal of hepatology*. 2011;55(6):1353–60.
47. Peymani P, Ghavami S, Yeganeh B, et al. Effect of chloroquine on some clinical and biochemical parameters in non-response chronic hepatitis C virus infection patients: pilot clinical trial. *Acta Bio-medica: Atenei Parmensis* 06 May. 2016;87(1):46–53.
48. Peymani P, Yeganeh B, Sabour S, et al. New use of an old drug: chloroquine reduces viral and ALT levels in HCV non-responders (a randomized, triple-blind, placebo-controlled pilot trial). *Canadian Journal of Physiology and Pharmacology*. 15 January 2016 .